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Recently the journal Performance Enhancement & Health put out a call to produce a special issue on the 
dark side of human enhancement, including the use of legal and illegal substances, leading us to ponder 
whether the “dark side” of anabolic-androgenic steroids (from here on, “steroids”) has been overstated. 
In this commentary, we will briefly engage with this question by unpacking what we describe here as the 
“narrative of harm”, which tends to dominate discourses on steroid use in wider society. We then 
consider an alternative perspective on steroid use which focuses on the users’ experience and 
understanding, with particular attention to the role of pleasure. Finally, we conclude by exploring some 
of the negative policy consequences arising from the dominance of the “narrative of harm” and advance 
a regulatory approach grounded in rational research and informed discussions around both the 
pleasures and pains of steroid use. A more developed version of this argument can be found in the 
forthcoming collection Human Enhancement Drugs, published by Routledge in 2019 (Mulrooney, van de 
Ven, McVeigh, & Collins, forthcoming).  
 
The Narrative of Harm 
The most pervasive facet of the narrative of harm is that steroids pose serious health risks. Media and 
political discourses in particular tend to provide a sense that using these drugs is “akin to being a gun 
powder keg about to explode” (Soni & Nasrulla, 2018) or that users are on a “deadly crusade to get 
ripped” (Gorman, 2017). Yet, the reality is much more complex. For instance, the most commonly 
identified side effects are cosmetic in nature, such as oily skin (leading to acne) and fluid retention, 
which are generally reversible with cessation (Andrews, Magee, Combest, Allard, & Douglas, 2018; van 
Amsterdam, Opperhuizen, & Hartgens, 2010). Nevertheless, in addition to health risks such as testicular 
atrophy, increased blood pressure, suppression of gonadotropins and reduced insulin sensitivity (see 
e.g. Rasmussen et al. 2016; 2017; 2017); Christou et al. 2017; Kanayama et al. 2015; Nieschlag & Vorona 
2015; Rahnema et al. 2014; Rasmussen et al. 2016; Pope et al. 2014) several long-term health risks have 
been associated with using steroids such as cardiovascular disease (Baggish et al., 2017) and cognitive 
deficiencies (Kaufman et al., 2015). Evidently, the potential for harm exists, however, such harms need 
to be contextualized. In a simple use vs. non-use dichotomy, of course people who use steroids are at 
greater risk of developing health harms related to their use than people who do not use. Indeed, the 
bottom line for current health policy is that non-medical steroid use is bad for your health.   
 
However, although it is often stated by health authorities and the media that steroids are harmful, data 
are lacking as to precisely how harmful they are. Most knowledge about the harmful effects of steroids is 
based on low level evidence, such as expert opinion, case reports or small observational studies, while 
clinical trials to study the efficacy and long-term effects of steroid use are absent (Smit & de Ronde, 2018). 
Yet, instead of acknowledging that we lack a comprehensive understanding of the health risks of steroid 
use, a “guilty until proven innocent” stance is often taken. Not only does this hamper our understanding 
of the health risks of these substances but also the advancement of medical research wanting to explore 
their therapeutic benefits. While the extent to which steroid use leads to critical health risks is unclear, 
there are other indicators we may draw on to gain a better understanding of the relative risks of these 
substances, for example, when comparing them to other illicit drugs. In a number of studies exploring 
relative drugs harms, steroids consistently appear low on the list for general harm as well as for physical, 
psychological and social harm to both users and society (e.g. Nutt, King, & Phillips, 2010; van Amsterdam, 
Nutt, Phillips, & van den Brink, 2015; van Amsterdam, Opperhuizen, Koeter, & van den Brink, 2010).  
 
Furthermore, we must also be considerate to relative risks between users. Indeed, wthere is evidence to 
suggest steroids do pose health risks, important contextual information is often left out such as, for 
example, the role of pre-existing health conditions, the use of unverified black-market products, the type 
of steroids used and/or the dosage and in particular, the length of steroid using career. For instance, years 
of high dosages may impair testosterone function and some users may not themselves recover completely 
from anabolic steroid induced hypogonadism (ASIH) without the assistance of testosterone replacement 
therapy (TRT). Yet, perhaps one of the key aspects of blurring the line between the “pleasures and pains” 
of steroid use is the failure to differentiate between use and abuse, though this is not foreign to discourses 
on drug use. Rather, it is the accumulation of factors, such as longer steroid cycles, increased dosages and 
poly-drug use, which increase the public health risk and, therefore, depending on their use patterns some 
users will run greater health risks than others. Taken together, discussions on steroid use must clearly 
distinguish between health harms that are likely to be centrally important to users in terms of both the 
probability of occurrence and potential severity, as well as the relativity of risk in terms of steroid use 
generally and between “typologies” of steroid users themselves (Christiansen, Vinther, & Liokaftos, 2017).  
 
Closely connected to individual health harms, a frequently cited side effect of non-medical steroid use is 
aggression and violence. Indeed, since the mid-1980s, the notion that steroid use leads to aggressive or 
violent behaviour became widespread, giving rise to the term ‘roid rage’, used to denote steroid-related 
aggression (Dunn, 2014). Once again, this facet of the narrative of harm is amplified by the media and law 
enforcement discourses which often recount how steroids played a central role in particularly brutal acts 
of violence such as, the case of wrestling star Chris Benoit (Chappell, 2007) or, more recently, the London 
Bridge terrorist attack (BBC, 2018). Although the animal literature has found a direct, positive relationship 
between testosterone and increased aggressive behaviour (McGinnis, 2006; Melloni, Connor, Xuan Hang, 
Harrison, & Ferris, 1997), providing important insights into some of the behavioural consequences of 
steroid use, it does not and cannot capture all aspects of the human experience. Indeed, studies that have 
examined the relationship between aggressive behaviour and substance use by humans show a much 
more complex picture. While testosterone may facilitate both aggressive and rewarding behaviour in 
humans (see Dreher et al, 2016), in general, the relationship between substance use (including steroids) 
and aggressive behaviour is likely accounted for by third variable factors, such as personality traits, 
neuropsychological risks, environmental influences, socio-economic status, poly-substance use and, with 
the exception of alcohol, is not causally related (Lundholm, Frisell, Lichtenstein, & Langstrom, 2015; 
Tomlinson, Brown, & Hoaken, 2016), highlighting the complexity of hormone/behaviour-relations.  
 
Lastly, the caricature of non-medical steroid users as narcissistic, self-absorbed ‘gym bros’ suffering from 
body image issues, provides an equally simplistic account of user motivations and ignores the spectrum 
of user typologies. In media articles, for example, steroid users are often portrayed as young adults or 
teenagers who are insecure about their body and are experiencing a “crisis of male ego” (Walsh, 2018) by 
seeking the “ripped Loved Island look” (Burrows, 2017). Yet, typically, a person’s first experience using 
steroids is reported to occur in their mid to late twenties (McVeigh & Begley, 2017), with many steroid 
users having an above average education and income, and not being involved in sports (Christiansen et 
al., 2017; Cohen, Collins, Darkes, & Gwartney, 2007). To this end, there is an increasing body of research 
which shows that there is substantial variability in steroid-using populations in terms of motivations for 
use, health risk potential and health seeking behaviours (Christiansen et al., 2017; van de Ven et al., 2018b; 
Zahnow et al., 2018). Indeed, while some use for cosmetic reasons (e.g., to increase muscle mass and 
strength) others will use these substances to improve sporting performance, for anti-ageing purposes, to 
increase energy levels and/or to recover more quickly from an injury (Begley et al., 2017).  
 
A specific subtype of body image disorder linked to this group is muscle dysmorphia, often referred to as 
“bigorexia” in the media, which was first described in the early 90s (Pope Jr, Katz, & Hudson, 1993). The 
main feature of muscle dysmorphia is body dissatisfaction, in particular regarding one’s muscles, which 
may lead individuals to use steroids, consume supplements, strictly control their diets, engage in excessive 
physical exercise, and so on (Olivardia, Pope, & Hudson, 2000). Yet, there is no solid evidence as to how 
many people who use steroids actually have or will develop a body image disorder, or what the association 
is between the two. While some studies point towards an association (e.g. Rohman, 2009), others do not 
find an association and, for example, show that the attachment style of a person is an important predictor 
for someone to develop muscle dysmorphia (e.g. Fabris, Longobardi, Prino, & Settanni, 2018). Perhaps 
most concerning, in a recent systematic review of the literature on muscle dysmorphia, Sandgren and 
Lavallee (2018) concluded that the “methodological quality of recent muscle dysmorphia research was 
considered low due to a lack of clinical samples, measurements not using validated cut-off scores, and the 
research designs”.  
 
The User’s Voice and the Pleasures of Steroid Use 
Research in the field of alcohol and psychoactive drugs has highlighted the importance of acknowledging 
the benefits and pleasurable effects of substance use and the use of substances by healthy individuals 
(e.g. Hamilton & Aldridge, 2019; Power, 2018; d'Angelo, Savulich, & Sahakian, 2017; Holt & Treloar, 2008; 
O’Malley & Valverde, 2004; Ritter, 2014; Winstock & Nutt, 2013). Following this line, an implication of the 
narrative of harm is that it tends to overlook and ignore the role of pleasure in the consumption of steroids 
and, even where this may be acknowledged, paternalism and morality tend to take precedence over 
individual choice. In terms of the latter point, it goes without saying that this position is at odds with a 
number of riskier socially accepted and legalized pursuits such as the consumption of tobacco and alcohol, 
and, more recently, surgical and non-surgical cosmetic enhancement.  
 
Indeed, with respect to these pursuits, Western liberal democracies generally concede that consenting 
adults have the right to choose pleasure at the risk of pain (or even injury or death) and we accept this in 
many facets of life more broadly (e.g. sport) so long individual freedoms do not impinge on the ‘common 
good’. Yet, there is a stark contrast between the way society treats cosmetic steroid use as compared to 
non-surgical cosmetic enhancement such as the use of Botox and dermal filler or surgical enhancement 
such as breast augmentation or blepharoplasty (eyelid surgery), despite the relative risks involved (Balk, 
Earley, Avendano, & Raman, 2016; Brennan, Wells, & Van Hout, 2018). Indeed, while both surgical and 
non-surgical procedures have become increasingly normalized and arguably celebrated (e.g., Vogue) as a 
personal prerogative of self-improvement (Featherstone, 2010), steroid use remains largely pathologized 
despite questions being raised about the relative harm of these substances. This may be, in part, because 
of the legal/regulatory context in which these respective practices occur, but that is only because policy 
makers have chosen to deal with this particular form of enhancement through repression.  
  
We often overlook the fact that there will be many users who will use these substances for their 
immediate gratification (e.g., feelings of strength) or delayed gratification from ‘higher’ objectives (e.g., 
constructive efforts/functional enhancement). Indeed, there is a plethora of self-reported data with 
regard to the role of “pleasures” in the consumption of steroids (e.g. Monaghan, 2001, 2002; Kimergård, 
2015; Underwood, 2017). For instance, while Monaghan (2002) notes that bodybuilders tend to sharply 
contrast themselves with ‘other’ drug takers, often based on their pursuit of a “higher objective than 
pleasure” in contrast to, for example, the pleasure of getting high, he also points out that “bodybuilders 
derive aesthetic pleasure from their own and other members’ body modification practices”, linked to both 
feelings and constructive efforts. In other words, while “the ‘highs’ associated with chemical bodybuilding 
are achieved rather than pharmacological”, they are nonetheless pleasure inducing and part of the appeal 
of drug taking in this context. In addition to the delayed gratification which comes from body/performance 
modification, it is not unusual for users to report pleasurable feelings such as increased libido, greater 
confidence and increased wellbeing and strength (Begley et al., 2017; Underwood, 2017). 
 
Given the centrality of pleasure for many users in the consumption of these substances, pleasure is an 
essential part of a coherent and reasoned response to steroid consumption. The current “pathology 
paradigm” (Mugford, 1988; cited in Moore, 2008) engrained in the narrative of harm is dominated almost 
exclusively by individual and social risks with little to no acknowledgment of pleasure as a benefit in its 
own right. This is particularly relevant considering the questions raised above with respect to absolute 
and relative risk, the notion of individual choice and a risk/benefit analysis. Perhaps most worrisome, 
failing to acknowledge the role of pleasure and other benefits in the consumption of these drugs may 
hinder our ability to address the phenomenon and ultimately curbs advances in regulatory frameworks.  
It is to this we now turn.  
 
Implications of the Narrative of Harm 
Our central point of contention with the narrative of harm is the way in which the dominance of the 
discourses that comprise it have come to occupy discussions around steroids to the exclusion of others. 
The key problem being that, without nuance, the public and policy-makers are presented with a distorted 
reality from which to respond to steroid use. Indeed, there are a number of serious implications driven by 
this narrative and the pre-cautionary principle it tends to emphasize. Chiefly, a narrative centred on public 
health harms, the potential for violent behaviour and psychological disturbance naturally prioritizes 
repressive means to combat the issue. Add to this the incompatibility of harm reduction with two other 
dominant narratives that tend to dominate discussion on steroids, that of doping in sport and the use of 
steroids by youth, and it is not surprising that punitive mechanisms lead the charge in what has been 
called the “war on doping”.  
 
Extreme examples include Denmark and Belgium where every-day gym users are subject to drug testing 
regimes with punitive implications (Christiansen, 2011; van de Ven, 2016; van de Ven & Mulrooney, 2017; 
van de Ven & Mulrooney, 2014). Furthermore, a number of countries (e.g. Australia, Sweden, and the US) 
have rescheduled steroids so that their production, sale and even consumption come with increasingly 
harsh penalties (van de Ven & Mulrooney, 2014). For example, increased attention on violence in Sydney’s 
night time economy formed part of the arguments which led to a raft of legislative changes, including 
rescheduling steroids as a schedule I drug and subsequently increasing the maximum sentence for the 
illicit supply of steroids to 25 years (van de Ven, Dunn, & Mulrooney, 2018a). As evidenced in other drug 
markets (e.g. Caulkins & Reuter, 2006; Lenton & Heale, 2000; Volkow, Poznyak, Saxena, Gerra, & Network, 
2017), this repressive approach of criminalizing use has resulted in its own set of harms to users such as 
subjecting users to prison or felony convictions, as happens in some jurisdictions, which can destroy a 
person’s employment and educational opportunities, adversely impacting their own lives and the lives of 
their families.  
 
Furthermore, even where harm reduction initiatives are advanced, the narrative of harm surrounding 
steroids leads to the natural conclusion that these drugs need to be controlled if not by the threat of 
punishment than at least by making them more difficult to access. The issue with this, as much research 
has shown (e.g. Caulkins & Reuter, 2006), is that where there is demand there is supply and so users 
continue to consume, however, their sources and consumption practices are clandestine instead of 
medically regulated (Fincoeur, van de Ven, & Mulrooney, 2015). Indeed, many of the health harms so 
central to the narrative of harm could be more easily discovered by adopting a public health-oriented 
model of addressing the issue of steroid consumption. For instance, by not accepting the pleasurable 
effects or low risks of using certain pharmaceuticals, healthcare providers, such as physicians, may be 
dissuaded from providing medical services to people who choose to continue to their pharmaceutical drug 
use for non-medical reasons (i.e., non-medical steroid use). Importantly, many users know harm is only 
part of the story and so the primary definers of “the steroid problem” may lose credibility. Thus, it is 
perhaps not surprising that steroid users tend to report rather negative experiences in their interactions 
with medical professionals (Dunn, Henshaw, & McKay, 2016; Hope et al., 2013; Zahnow, McVeigh, Ferris, 




This commentary should not be read as an attempt to deny any harmful properties nor to promote the 
use of these substances. Rather, our intention is to question and critique the dominance of the narrative 
of harm, in light of a more nuanced appraisal of the evidence, and, most importantly, to highlight that in 
over-stating the dark side of steroids a skewed narrative has emerged which has the potential to 
increase harms in the name of public protection. The failure of the media, politicians and some 
academics to report this more complex and nuanced picture, focusing instead on isolated case reports 
of harms and tragedies, misinforms the public and policy-makers. This understandably directs the 
dialogue and policy into punitive territory and sows’ mistrust in those with otherwise benevolent 
intentions. Alternatively, we argue, that a more realistically balanced approach to these drugs, absent 
from morality and sensationalism, considerate of the users’ perspective and backed by scientific 
research, increases the capacity to reduce evidenced harms. Indeed, while there is evidence to suggest 
steroids are harmful, the narrative of harm which tends to dominate discourses on steroid consumption 
often fails to consider questions around the relative nature of harms and to weigh such risks against a 
plethora of self-reported outcomes due to functional enhancement, in addition to any potential 
immediate gratification for users. As such, it will help us to inject pleasure into the discourses on steroid 
use and its regulation, to have rational and critical debates on achieving pleasure while minimizing 
established associated risks, something that is particularly important in a world that appears increasingly 
willing and indeed eager to explore the opportunities for human enhancement. 
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